Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney Function (ALBLOCK-2)

Lene Boesby

Status and phase

Terminated

Phase 3

Conditions

Chronic Kidney Disease

Treatments

Drug: Eplerenone

Study type

Interventional

Funder types

Other

Identifiers

NCT01100203

ALBLOCK-2

Details and patient eligibility

About

Patients with Chronic Kidney Disease (CKD) have a poor prognosis primarily due to cardiovascular disease. The cardiovascular risk can be assessed by measurements of arterial stiffness. A decrease in stiffness has been shown to decrease the risk of cardiovascular disease as well as death. Most of the CKD population also have hypertension and the control of blood pressure is one of the corner stones in inhibition of disease progression. Using drugs that specifically block the renin-angiotensin-system for blood pressure control has been shown to have a beneficial impact on inhibition of progression beyond that of the achieved blood pressure control. It has been reported that inhibition of the hormone aldosterone has a positive effect on survival in patients with heart failure, hypertension and diabetic as well as on-diabetic nephropathy.

This study undertakes the investigation of the influence on arterial stiffness of adding an aldosterone receptor inhibitor to the medication CKD patients are already taking. Besides the primary end point which is Pulse wave velocity (PWV), arterial stiffness is also quantified thorough ambulatory blood pressure measurements.

Enrollment

54 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

≥ 18 years age ≤ 80 years age
voluntarily signed informed consent
15 ml/min/1,73 m2 ≤ estimated Glomerular Filtration Rate < 60 ml/min/1,73 m2
BP ≥ 130/80 mmHg or undergoing anti-hypertensive treatment

Exclusion criteria

p-potassium is > 5.0 mM
allergy to contents
treated with spironolactone
treated with potent inhibitors of CYP3A4 (see SPC for details)
treated with lithium, ciclosporin, tacrolimus, prednisolone, or other immunosuppressing drug
inborn errors of metabolism (see SPC for details)
pregnancy or lactation
fertile woman, not using safe contraception devices
dementia or other psychiatric disorder, making understanding of the study conditions impossible
other severe, chronic illness besides CKD, including liver insufficiency, according to investigators' judgement
vascular surgery including stenting or graft implantation on a. brachialis, aorta or the carotid arteries
systolic BP > 200 mmHg
immeasurable pulse amplitude